Hodogaya Chemical Co., the Tokyo-listed maker of phosgene-based specialty chemicals, said it completed the takeover of Hungary's Framochem Francia-Magyar Finomkemiai Kft on August 25, 2026, closing a deal first announced in March. Framochem becomes a wholly owned consolidated subsidiary after Hodogaya bought all of its equity under a quota purchase agreement.
| Item | Detail |
|---|---|
| Target company | Framochem Francia-Magyar Finomkemiai Kft (Hungary) |
| Stake acquired | 100%, now a wholly owned consolidated subsidiary |
| Deal mechanism | Quota Purchase Agreement |
| Announced | March 27, 2026 |
| Completed | August 25, 2026 |
| Framochem founded | 1993 |
| Hodogaya's first phosgene production | 1926, in Japan |
| Strategic plan | CODE 2030, five years to the year ending March 2031 |
The purchase gives Hodogaya its first manufacturing base inside Europe. Framochem, founded in 1993, supplies active pharmaceutical ingredients and intermediates to European drugmakers and chemical groups, according to the disclosure. Hodogaya has until now made and exported its phosgene derivatives entirely from Japan, where it opened the country's first phosgene production line in 1926. Pairing that domestic base with a European plant creates what the company calls a "Japan-Europe double hub," which it says is meant to secure a leading niche position in the phosgene-derivatives market worldwide.
The deal is the opening move under Hodogaya's new five-year plan, CODE 2030, unveiled on May 15 this year and running through the year ending March 2031. The company has designated the first three years of that plan a "transformation" phase built on portfolio changes and mergers and acquisitions, and it describes the Framochem purchase as its top-priority step for expanding the specialty chemicals business, specifically phosgene derivatives, inside its functional resins segment.
Hodogaya's president said in the release that he visited Framochem twice more than a decade ago and had felt a long-standing connection to the company's technical strength since then. The closing lands in a year Hodogaya marks its 110th anniversary and the 100th anniversary of its first phosgene production. Framochem's managing director and chief executive, Tamás Vörös, called the deal "a great honor" and pointed to combining the Hungarian company's European market presence and manufacturing capability with Hodogaya's century of expertise.
What the deal does to earnings is still unclear. Hodogaya said the effect on its consolidated results for the fiscal year ending March 2027 remains under review, and that it will disclose any forecast revision promptly if one becomes necessary. The filing gives no purchase price, revenue contribution, or production capacity figures for Framochem, so the near-term financial weight of Hodogaya's first cross-border acquisition under CODE 2030 is, for now, unstated.